Jupiter Life Lin

Jupiter Life Line Hospitals reported a robust Q1 FY26 with total income reaching ₹347.6 crores, marking a 20.5% year-on-year increase. EBITDA also grew significantly by 19.6% to ₹78.1 crores, maintaining a healthy margin of 22.5%. However, Net Profit (PAT) saw a slight decline of 1.6% year-on-year, resulting in a PAT margin of 12.6%. This PAT compression is primarily attributed to increased depreciation and finance costs, a trend management expects to continue for the full financial year.

The company's three greenfield projects in Dombivli, Mira Road, and the second Pune Hospital are progressing as planned. For Dombivli, approximately ₹200 crores has been incurred, with another ₹200 crores expected in the coming months to reach completion. The Pune-Baner facility is set to commission a new ICU towards the end of the year. Management indicated that Pune and Indore, benefiting from increased capacity, are expected to drive more growth than Thane this financial year.

Operational metrics for Q1 FY26 showed an average occupancy rate of 60.1%, a relative dilution compared to 63.9% last year due to the addition of new Census Beds. However, absolute occupancy and overall patient volume increased by 11.7% year-on-year to 2.6 lakhs. The Average Revenue Per Occupied Bed (ARPOB) stood at ₹67,300, driven by a combination of inflation-linked price hikes across all locations and case mix optimization, particularly in the less mature Indore hospital. The payor mix saw 56.3% from insurance, 42.3% from self-payers, and 1.4% from government schemes, with management noting a lasting nationwide trend of increasing insurance penetration.

Jupiter Life Line Hospitals maintains a strong liquidity position with a net cash balance of ₹275 crores, comprising ₹600 crores in cash against a total debt of ₹325 crores. Capital expenditure for Dombivli is expected to require an additional ₹200 crores in the near term. The company also invested ₹5 crores in a new 1.2 megawatt solar power plant in Madhya Pradesh, which is projected to yield annual opex savings of approximately ₹1 crore over its 20-25 year lifespan. Discussions are also underway to add 3 megawatts of solar capacity in Maharashtra.

Management anticipates that while EBITDA margins will likely be preserved, the widening gap between PAT and EBITDA due to higher depreciation and finance costs will lead to lower PAT margins for the full financial year. The new Dombivli hospital is expected to incur negative EBITDA in its first year of operation, causing some compression at the consolidated level, but is targeted to achieve EBITDA breakeven by its second year. Peak occupancy for all hospitals is expected to be in the mid-70% range.

A significant regulatory challenge was highlighted regarding the planned bed expansion at the Thane hospital, where the Environment Committee is not accepting applications due to an ongoing Supreme Court case, leading to an indefinite delay. Despite a new peer hospital commencing operations in Thane, management confirmed no impact on Jupiter's patient volumes or human resources, with performance remaining in line with previous trends.